ES2652654T3 - Métodos para preparar ribósido de nicotinamida y derivados del mismo - Google Patents

Métodos para preparar ribósido de nicotinamida y derivados del mismo Download PDF

Info

Publication number
ES2652654T3
ES2652654T3 ES14744082.0T ES14744082T ES2652654T3 ES 2652654 T3 ES2652654 T3 ES 2652654T3 ES 14744082 T ES14744082 T ES 14744082T ES 2652654 T3 ES2652654 T3 ES 2652654T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
optionally
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14744082.0T
Other languages
English (en)
Spanish (es)
Inventor
Marie MIGAUD
Philip REDPATH
Kerri CROSSEY
Mark Doherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Application granted granted Critical
Publication of ES2652654T3 publication Critical patent/ES2652654T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES14744082.0T 2013-07-29 2014-07-24 Métodos para preparar ribósido de nicotinamida y derivados del mismo Active ES2652654T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1313465.5A GB201313465D0 (en) 2013-07-29 2013-07-29 Methods of preparing nicotinamide riboside and derivatives thereof
GB201313465 2013-07-29
PCT/EP2014/065971 WO2015014722A1 (en) 2013-07-29 2014-07-24 Methods of preparing nicotinamide riboside and derivatives thereof

Publications (1)

Publication Number Publication Date
ES2652654T3 true ES2652654T3 (es) 2018-02-05

Family

ID=49167061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14744082.0T Active ES2652654T3 (es) 2013-07-29 2014-07-24 Métodos para preparar ribósido de nicotinamida y derivados del mismo

Country Status (14)

Country Link
US (7) US10000519B2 (enExample)
EP (2) EP3321274A1 (enExample)
JP (1) JP6208352B2 (enExample)
KR (2) KR102414886B1 (enExample)
CN (2) CN108707174A (enExample)
AU (4) AU2014298629B2 (enExample)
BR (1) BR112016001774B1 (enExample)
CA (2) CA3192957A1 (enExample)
ES (1) ES2652654T3 (enExample)
GB (1) GB201313465D0 (enExample)
HK (1) HK1255037A1 (enExample)
MX (1) MX349969B (enExample)
WO (1) WO2015014722A1 (enExample)
ZA (1) ZA201802315B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
WO2015186068A1 (en) * 2014-06-02 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
CN106715454B (zh) * 2014-07-24 2020-06-16 格雷斯公司 烟酰胺核苷的结晶形式
CA2978069C (en) 2015-03-09 2021-10-12 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
BR112017019696A2 (pt) * 2015-03-16 2018-09-04 ChromaDex Inc. composto e usos de um composto
US10392414B2 (en) 2015-07-15 2019-08-27 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
AU2016302005B2 (en) 2015-08-05 2021-03-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2017079195A1 (en) * 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
WO2017145151A1 (en) 2016-02-23 2017-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Process for preparation of nicotinamide riboside (nr) and cosmetic composition comprising (nr and a phosphate-binding agent
US10000520B2 (en) 2016-03-16 2018-06-19 ChromaDex Inc. B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
MX393076B (es) 2016-04-20 2025-03-24 Chromadex Inc Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
GB2553001A (en) * 2016-08-19 2018-02-21 The Queen's Univ Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
EP3538099A4 (en) 2016-11-11 2020-06-17 The Queen's University of Belfast EFFICIENT AND SCALABLE SYNTHESIS OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS OF THEM, ADENYLYDINUCLEOTIDE CONJUGATES THEREOF AND NEW-WAY CRYSTALS
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
JP2020526511A (ja) * 2017-06-30 2020-08-31 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドの合成方法
WO2019122084A1 (en) 2017-12-22 2019-06-27 Stemtek Therapeutics, S.L. Process for the preparation of nicotinamide riboside chloride derivatives
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
WO2019152416A1 (en) 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN110283221A (zh) * 2018-03-19 2019-09-27 药源药物化学（上海）有限公司 杂环化合物的制备和纯化方法
CN110452277A (zh) * 2018-05-07 2019-11-15 明特奇点医疗科技(成都)有限公司 一种烟酰胺核糖的制备方法
CN113490675B (zh) * 2018-05-22 2026-01-09 江普斯塔特生育有限公司 作为抗衰老剂的烟酸核苷的氨基酸盐
US12403152B2 (en) 2018-06-21 2025-09-02 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (NAD+) precursor and at least one ketone or ketone precursor
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
KR102060374B1 (ko) * 2018-12-14 2019-12-30 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CN119684381A (zh) 2019-07-19 2025-03-25 生物合成股份公司 烟酰胺呋喃核糖苷盐的结晶形式以及包含其的营养补充剂和药物组合物
CN114555619A (zh) * 2019-08-14 2022-05-27 麦德龙国际生物科技有限责任公司 用于烟酰胺腺嘌呤二核苷酸的差分调节的化合物和组合物
CN110642897B (zh) * 2019-09-27 2021-04-06 武汉一若生物材料有限公司 一种β-烟酰胺核糖氯化物的制备方法
CN110658224B (zh) * 2019-10-15 2022-11-22 中国中医科学院中药研究所 一种氢核磁定量分析技术测定nmn绝对含量的方法
CN111153953A (zh) * 2020-01-07 2020-05-15 杭州洁汉化工有限公司 一种烟酰胺核糖氯化物的高效合成方法
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
CN111647032B (zh) * 2020-06-29 2023-02-24 上海舒泽生物科技研究所 一种β-烟酰胺单核苷酸的合成方法
CN111848710A (zh) * 2020-08-20 2020-10-30 深圳市迪克曼科技开发有限公司 烟酰胺核糖及其还原态、盐的制备方法
US20230271995A1 (en) * 2020-09-15 2023-08-31 Societe Des Produits Nestle S.A. Methods for producing dihydronicotinamide riboside from nicotinamide riboside chloride
CN112851730B (zh) * 2021-01-08 2023-02-21 厦门瑞林药业有限公司 一种nmn中间体nr氯化物合成方法
WO2022233923A1 (en) 2021-05-04 2022-11-10 Bohan & Co As. A process for synthesis of nicotinamide riboside chloride (nrcl)
IL308577A (en) 2021-05-27 2024-01-01 Metro Int Biotech Llc Crystalline solids of nicotinic acid mononucleotides and their esters and methods for their preparation and use
AU2023227391A1 (en) 2022-03-04 2024-10-17 Bohan & Co As. Process for synthesis of 1,4-dihydronicotinamide riboside (nrh) from nicotinamide-beta-riboside triacetate chloride (nra-cl)
CN116462727A (zh) * 2023-04-23 2023-07-21 安徽瑞邦生物科技有限公司 一种β-烟酰胺核糖氯化物的制备方法
WO2024259359A2 (en) * 2023-06-14 2024-12-19 ChromaDex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633158A (en) 1991-10-23 1997-05-27 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
ES2670927T3 (es) * 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
WO2011081942A1 (en) 2009-12-14 2011-07-07 Cornell University Activation and activators of sirt5
KR20130044382A (ko) * 2010-03-01 2013-05-02 마이렉시스 인코포레이티드 화합물 및 그의 치료 용도
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
RU2016149767A (ru) * 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение

Also Published As

Publication number Publication date
KR20160043974A (ko) 2016-04-22
CA3192957A1 (en) 2015-02-05
US20220259250A1 (en) 2022-08-18
MX349969B (es) 2017-08-23
AU2020201254B2 (en) 2022-05-26
US20260062436A1 (en) 2026-03-05
AU2018211238A1 (en) 2018-08-16
KR102303966B1 (ko) 2021-09-24
US20240101588A1 (en) 2024-03-28
US20180186824A1 (en) 2018-07-05
CA2918955C (en) 2023-05-09
HK1255037A1 (en) 2019-08-02
AU2014298629A1 (en) 2016-02-11
US10000519B2 (en) 2018-06-19
KR20210038718A (ko) 2021-04-07
CN105636973A (zh) 2016-06-01
WO2015014722A1 (en) 2015-02-05
AU2022203196B2 (en) 2023-11-23
US11981698B2 (en) 2024-05-14
BR112016001774A2 (pt) 2017-08-01
EP3321274A1 (en) 2018-05-16
US20160168184A1 (en) 2016-06-16
JP6208352B2 (ja) 2017-10-04
US11584770B2 (en) 2023-02-21
JP2016530248A (ja) 2016-09-29
US20200291055A1 (en) 2020-09-17
US12252506B2 (en) 2025-03-18
AU2022203196A1 (en) 2022-06-02
EP3027635B1 (en) 2017-09-20
EP3027635A1 (en) 2016-06-08
AU2020201254A1 (en) 2020-03-12
BR112016001774B1 (pt) 2021-06-22
GB201313465D0 (en) 2013-09-11
HK1218918A1 (en) 2017-03-17
CN108707174A (zh) 2018-10-26
AU2014298629B2 (en) 2018-08-16
CN105636973B (zh) 2018-06-01
US20240239831A1 (en) 2024-07-18
US10815262B2 (en) 2020-10-27
KR102414886B1 (ko) 2022-07-01
NZ716277A (en) 2021-03-26
BR112016001774A8 (pt) 2020-01-21
ZA201802315B (en) 2023-02-22
MX2016001211A (es) 2016-10-28
CA2918955A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
ES2652654T3 (es) Métodos para preparar ribósido de nicotinamida y derivados del mismo
JPH05186494A (ja) スピカマイシン誘導体およびそれを含む抗腫瘍剤
HK1218918B (en) Methods of preparing nicotinamide riboside and derivatives thereof
NZ716277B2 (en) Methods of preparing nicotinamide riboside and derivatives thereof
JPH0633263B2 (ja) ７−ヒドロキシグアニン誘導体及びその製造方法並びにそれを有効成分とする抗腫瘍剤
CN112209976B (zh) 一种地西他滨中间体化合物ⅴ
TAKAMURA et al. Syntheses and antitumor activities of N6, N6-dimethyladenosine carboxylate analogues
JPH0873489A (ja) スピカマイシン誘導体およびそれを含む抗腫瘍剤
JPWO1990015812A1 (ja) ２―アルキニルアデノシンの合成中間体、該合成中間体の製造法、該合成中間体を利用した２―アルキニルアデノシンの製造法および安定な２―アルキニルアデノシン誘導体
EP0095292A1 (en) 5-(2-halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections"
JPH0343261B2 (enExample)